Breaking News

Axplora Announces €50M Investment in GLP-1 Manufacturing at France Site

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Axplora, a global CDMO for API small molecule and ADC manufacturing, announces the investment of €50 million in its Mourenx site in Southwest France. Specializing in large-scale API industrial chemistry and chromatography, this project will enhance Mourenx’s capabilities, positioning it as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics. Upgrading infrastructure and capabilities at Mourenx enhances its peptide pur...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters